This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
acute respiratory | 388 |
coronavirus disease | 374 |
en el | 359 |
respiratory syndrome | 337 |
clinical trials | 309 |
pacientes con | 300 |
severe acute | 293 |
clinical trial | 258 |
cq hcq | 249 |
en pacientes | 240 |
novel coronavirus | 235 |
syndrome coronavirus | 230 |
se recomienda | 222 |
qt interval | 221 |
los pacientes | 212 |
systematic review | 209 |
lupus erythematosus | 203 |
qtc prolongation | 202 |
severe covid | 196 |
hospitalized patients | 192 |
author funder | 191 |
granted medrxiv | 191 |
con covid | 187 |
rheumatoid arthritis | 186 |
copyright holder | 184 |
systemic lupus | 184 |
antiviral activity | 166 |
patients treated | 165 |
randomized clinical | 160 |
side effects | 158 |
version posted | 157 |
viral load | 153 |
made available | 146 |
international license | 144 |
qt prolongation | 140 |
en los | 137 |
adverse effects | 136 |
observational study | 134 |
intensive care | 129 |
controlled trial | 128 |
critically ill | 122 |
el uso | 121 |
control group | 120 |
adverse events | 118 |
lopinavir ritonavir | 115 |
del paciente | 113 |
medrxiv preprint | 109 |
doc id | 108 |
cord uid | 108 |
peer review | 106 |
hcq treatment | 102 |
ill patients | 102 |
observational studies | 101 |
mg kg | 100 |
randomized controlled | 100 |
para el | 97 |
cohort study | 96 |
el paciente | 95 |
clinical studies | 95 |
viral replication | 95 |
por covid | 94 |
twice daily | 93 |
mechanical ventilation | 92 |
con el | 92 |
respiratory distress | 92 |
care unit | 91 |
risk factors | 89 |
interval prolongation | 88 |
hcq use | 88 |
type i | 86 |
mg twice | 86 |
distress syndrome | 81 |
sample size | 81 |
patients receiving | 77 |
increased risk | 76 |
con sospecha | 76 |
hcq group | 75 |
united states | 74 |
immune response | 72 |
case series | 71 |
paciente con | 71 |
antiviral effects | 71 |
sin embargo | 71 |
hcq alone | 71 |
rheumatic diseases | 70 |
antimalarial drugs | 70 |
qtc interval | 69 |
convalescent plasma | 68 |
viral infections | 67 |
chloroquine phosphate | 67 |
patients hospitalized | 66 |
vitro antiviral | 66 |
significant difference | 66 |
con un | 66 |
host cell | 65 |
hcq may | 64 |
rights reserved | 63 |
clinical improvement | 63 |
cytokine storm | 63 |
virus infection | 62 |
viral entry | 62 |
en un | 62 |
autoimmune diseases | 62 |
hcq azm | 61 |
sars coronavirus | 61 |
middle east | 60 |
received hcq | 60 |
heart failure | 59 |
east respiratory | 59 |
viral clearance | 58 |
viral shedding | 58 |
con una | 58 |
spike protein | 58 |
systematic reviews | 58 |
standard care | 58 |
label non | 57 |
treating covid | 57 |
health organization | 57 |
world health | 57 |
per day | 57 |
new york | 57 |
less toxic | 56 |
viral rna | 56 |
clinical efficacy | 56 |
higher risk | 56 |
disease severity | 55 |
optimized dosing | 55 |
el manejo | 55 |
inflammatory cytokines | 54 |
two groups | 54 |
mg day | 54 |
converting enzyme | 54 |
se debe | 54 |
clinical characteristics | 54 |
por sars | 53 |
dosing design | 53 |
statistically significant | 52 |
posted june | 52 |
ventricular arrhythmia | 52 |
without azithromycin | 52 |
supplementary table | 52 |
respiratory tract | 52 |
el riesgo | 52 |
pacientes en | 52 |
coronavirus infection | 52 |
un estudio | 51 |
binding energy | 51 |
mg daily | 51 |
se ha | 51 |
receiving hcq | 51 |
mortality rate | 51 |
drug administration | 50 |
por el | 50 |
moderate covid | 50 |
hospital mortality | 50 |
respiratory failure | 49 |
infected patients | 49 |
inhibiting sars | 48 |
among patients | 48 |
antiviral drugs | 47 |
combination therapy | 47 |
hospitalized covid | 47 |
ebola virus | 47 |
patients infected | 47 |
hcq therapy | 47 |
immune system | 46 |
small sample | 46 |
severe disease | 46 |
el tratamiento | 46 |
se puede | 46 |
ec values | 45 |
health care | 45 |
cuidados intensivos | 45 |
randomized trial | 45 |
infectious diseases | 44 |
retrospective cohort | 44 |
en las | 44 |
cell entry | 44 |
el grupo | 43 |
cardiovascular disease | 43 |
clinical benefit | 43 |
controlled trials | 43 |
experimental studies | 42 |
healthcare workers | 41 |
effectively inhibit | 41 |
viral infection | 41 |
cardiac complications | 41 |
virus replication | 41 |
hcq az | 41 |
lung injury | 41 |
associated pneumonia | 41 |
ventricular arrhythmias | 40 |
safety profile | 40 |
emergency use | 40 |
emerged novel | 40 |
loading dose | 40 |
performed using | 40 |
diabetes mellitus | 40 |
recently emerged | 40 |
propensity score | 40 |
randomised controlled | 40 |
clinical outcomes | 39 |
chloroquine effectively | 39 |
significant differences | 39 |
public health | 39 |
plasma convaleciente | 39 |
toxic derivative | 39 |
ng ml | 39 |
por lo | 39 |
retrospective study | 39 |
high dose | 38 |
epithelial cells | 38 |
hydroxychloroquine sulfate | 38 |
logistic regression | 38 |
disease progression | 38 |
apparent efficacy | 38 |
necrosis factor | 38 |
en cuenta | 38 |
en una | 38 |
vitro studies | 38 |
total aes | 37 |
shown apparent | 37 |
low dose | 37 |
present study | 37 |
confirmed covid | 37 |
host cells | 37 |
human coronavirus | 36 |
clinical course | 36 |
included studies | 36 |
exposure prophylaxis | 36 |
cardiac arrest | 36 |
heart disease | 36 |
serious adverse | 36 |
posted november | 36 |
may also | 35 |
treatment group | 35 |
controlled clinical | 35 |
molecular docking | 34 |
high risk | 34 |
animal models | 34 |
label use | 34 |
tumor necrosis | 34 |
several studies | 34 |
patients received | 34 |
clinical data | 34 |
antiviral effect | 34 |
pilot study | 33 |
antimalarial drug | 33 |
treat covid | 33 |
first day | 33 |
human immunodeficiency | 33 |
coronavirus pneumonia | 33 |
con los | 33 |
spike glycoprotein | 33 |
posted may | 33 |
body weight | 33 |
i ifn | 33 |
ventricular tachycardia | 33 |
significant effect | 32 |
hcq plus | 32 |
mg per | 32 |
retinal toxicity | 32 |
significantly higher | 32 |
immunodeficiency virus | 32 |
hydroxychloroquine use | 32 |
todos los | 32 |
hcq monotherapy | 32 |
case report | 32 |
another study | 32 |
hcq mono | 32 |
disease course | 31 |
treatment options | 31 |
drug repurposing | 31 |
use authorization | 31 |
primary outcome | 31 |
one patient | 31 |
corrected qt | 31 |
connective tissue | 31 |
antiviral agents | 31 |
en su | 30 |
myocardial infarction | 30 |
en uci | 30 |
severe cases | 30 |
cardiac toxicity | 30 |
within days | 30 |
immune responses | 30 |
clinical practice | 30 |
chloroquine hydroxychloroquine | 30 |
se han | 30 |
day follow | 30 |
early treatment | 30 |
long qt | 30 |
sle patients | 30 |
potent inhibitor | 30 |
su uso | 29 |
antiphospholipid syndrome | 29 |
protease inhibitors | 29 |
open label | 29 |
pao fio | 29 |
study design | 29 |
clinical features | 29 |
trial hydroxychloroquine | 29 |
odds ratio | 29 |
included patients | 29 |
day mortality | 29 |
cov infection | 29 |
influenza virus | 29 |
two drugs | 29 |
los estudios | 29 |
daily dose | 29 |
inflammatory response | 28 |
debe ser | 28 |
con sdra | 28 |
chloroquine diphosphate | 28 |
taking hcq | 28 |
rna viruses | 28 |
among hospitalized | 28 |
adjunctive therapy | 28 |
como el | 28 |
dosing regimen | 28 |
compassionate use | 28 |
shedding duration | 28 |
mg bid | 28 |
control arm | 28 |
study conducted | 28 |
clinical evidence | 28 |
puede ser | 27 |
induced hyperpigmentation | 27 |
coronavirus infections | 27 |
study using | 27 |
icu admission | 27 |
updated meta | 27 |
prolonging drugs | 27 |
dosing regimens | 27 |
like receptor | 27 |
healthy volunteers | 27 |
critical care | 27 |
pk pd | 27 |
cardiac side | 27 |
hcq azi | 27 |
nucleic acid | 27 |
new insights | 27 |
recent study | 27 |
del virus | 27 |
immune cells | 27 |
rna polymerase | 27 |
es un | 27 |
using hcq | 27 |
new coronavirus | 27 |
patients admitted | 27 |
retrospective analysis | 26 |
lower mortality | 26 |
vitro activity | 26 |
hcq mg | 26 |
adult patients | 26 |
dose group | 26 |
microbiological effect | 26 |
ace receptor | 26 |
antirheumatic drugs | 26 |
dendritic cells | 26 |
old drug | 26 |
hospital stay | 26 |
el cual | 26 |
type diabetes | 26 |
inclusion criteria | 26 |
study showed | 26 |
mouse model | 26 |
posted july | 26 |
creative commons | 26 |
authors declare | 26 |
blood levels | 25 |
main protease | 25 |
york state | 25 |
molecular dynamics | 25 |
antiviral clearance | 25 |
therapeutic options | 25 |
cuidado intensivo | 25 |
chloroquine inhibits | 25 |
control groups | 25 |
el momento | 25 |
rapid antiviral | 25 |
widely used | 25 |
symptom onset | 25 |
prolonged qt | 25 |
en este | 25 |
three times | 25 |
heart rhythm | 25 |
el inicio | 25 |
cl pro | 25 |
cardiac aes | 25 |
one study | 25 |
congestive heart | 24 |
cardiac arrhythmias | 24 |
en contra | 24 |
several clinical | 24 |
infection treated | 24 |
testing positive | 24 |
virus entry | 24 |
sobre el | 24 |
kcal mol | 24 |
viral carriage | 24 |
endosomal ph | 24 |
en caso | 24 |
comparison group | 24 |
results showed | 24 |
pilot observational | 24 |
baseline qtc | 24 |
teniendo en | 24 |
moderate coronavirus | 24 |
studies included | 24 |
statistical analysis | 24 |
hydroxychloroquine treatment | 24 |
original paper | 24 |
also found | 24 |
side effect | 24 |
el tiempo | 23 |
postexposure prophylaxis | 23 |
renal impairment | 23 |
cell culture | 23 |
even though | 23 |
informed consent | 23 |
membrane fusion | 23 |
cytokine production | 23 |
qt prolonging | 23 |
antigen presentation | 23 |
ongoing clinical | 23 |
prolongation associated | 23 |
hcq also | 23 |
si el | 23 |
kg day | 23 |
severely ill | 23 |
el personal | 23 |
oxygen therapy | 23 |
acute lung | 23 |
cytokine release | 23 |
adverse reactions | 23 |
confirmed cases | 23 |
hcq azithromycin | 23 |
review board | 23 |
viral particles | 23 |
available data | 22 |
consentimiento informado | 22 |
es una | 22 |
hydroxychloroquine azithromycin | 22 |
potential therapeutic | 22 |
high doses | 22 |
del estado | 22 |
corona virus | 22 |
prolonged qtc | 22 |
narrative review | 22 |
interim guidance | 22 |
patients testing | 22 |
significant reduction | 22 |
cell activation | 22 |
untested patients | 22 |
positive effect | 22 |
plasma concentrations | 22 |
selection bias | 22 |
atrial fibrillation | 22 |
sars cov | 22 |
institutional review | 22 |
tratamiento con | 22 |
cardiac injury | 22 |
clinical management | 22 |
drug therapy | 22 |
virus disease | 22 |
recent studies | 21 |
also showed | 21 |
qt intervals | 21 |
dosing schemes | 21 |
para los | 21 |
upper respiratory | 21 |
tissue diseases | 21 |
heart rate | 21 |
studies showed | 21 |
prolonging medications | 21 |
los casos | 21 |
weak bases | 21 |
public profile | 21 |
mcg ml | 21 |
reactive protein | 21 |
factors associated | 21 |
drug interactions | 21 |
protective effect | 21 |
coronary artery | 21 |
para pacientes | 21 |
i interferon | 21 |
falla respiratoria | 21 |
states veterans | 20 |
veterans hospitalized | 20 |
tissue distribution | 20 |
cardiovascular events | 20 |
preliminary results | 20 |
hydroxychloroquine usage | 20 |
qt syndrome | 20 |
en china | 20 |
lung tissue | 20 |
mortality rates | 20 |
rheumatic disorders | 20 |
es el | 20 |
oxidative stress | 20 |
without concomitant | 20 |
para evitar | 20 |
chain reaction | 20 |
statistical significance | 20 |
concomitant azithromycin | 20 |
higher doses | 20 |
mainly mild | 20 |
es importante | 20 |
adults hospitalized | 20 |
blood concentrations | 20 |
estos pacientes | 20 |
median time | 20 |
chikungunya virus | 20 |
proinflammatory cytokines | 20 |
antiphospholipid antibodies | 20 |
case reports | 20 |
low doses | 20 |
severe respiratory | 20 |
mean age | 20 |
lung inflammation | 20 |
nasopharyngeal swab | 20 |
adverse event | 20 |
sudden cardiac | 20 |
hospital admission | 20 |
cardiac death | 20 |
significantly lower | 20 |
disease control | 20 |
mild covid | 20 |
release syndrome | 20 |
virus type | 19 |
protease inhibitor | 19 |
azithromycin among | 19 |
los cuales | 19 |
infected cells | 19 |
infectious peritonitis | 19 |
higher mortality | 19 |
del covid | 19 |
treated patients | 19 |
hcq arm | 19 |
feline infectious | 19 |
qtc ms | 19 |
plus azithromycin | 19 |
large number | 19 |
breast cancer | 19 |
cual se | 19 |
entre los | 19 |
type ii | 19 |
alto flujo | 19 |
mrna expression | 19 |
included reviews | 19 |
cell lines | 19 |
recovery trial | 19 |
patients without | 19 |
cardiovascular system | 19 |
cardiovascular risk | 19 |
zika virus | 19 |
hasta el | 19 |
lo tanto | 19 |
primary studies | 19 |
mortality risk | 19 |
spectrum antiviral | 19 |
una serie | 19 |
drug discovery | 18 |
comparative study | 18 |
con enfermedad | 18 |
reporting items | 18 |
study population | 18 |
forma rutinaria | 18 |
cuando se | 18 |
tratados con | 18 |
cell line | 18 |
vitro inhibition | 18 |
durante el | 18 |
global pandemic | 18 |
preliminary report | 18 |
dose cq | 18 |
recomienda en | 18 |
significant arrhythmias | 18 |
therapeutic effect | 18 |
chest ct | 18 |
hcq showed | 18 |
therapeutic efficacy | 18 |
polymerase chain | 18 |
six patients | 18 |
currently available | 18 |
preferred reporting | 18 |
rmd patients | 18 |
median age | 18 |
insulin sensitivity | 18 |
baseline characteristics | 18 |
artery disease | 18 |
terminal glycosylation | 18 |
las recomendaciones | 18 |
acuerdo con | 18 |
ischemic heart | 18 |
cell membrane | 18 |
study found | 18 |
regression model | 18 |
commonly used | 18 |
current evidence | 18 |
risk patients | 18 |
beneficial effects | 18 |
receptor binding | 18 |
se sugiere | 18 |
qt ratio | 18 |
either cq | 18 |
solidarity trial | 18 |
neither drug | 18 |
interferon beta | 18 |
increased mortality | 18 |
task force | 18 |
risk factor | 18 |
viral loads | 18 |
cyclic gmp | 18 |
los efectos | 18 |
high vs | 18 |
severe pneumonia | 18 |
lower respiratory | 17 |
en covid | 17 |
also reported | 17 |
cq treatment | 17 |
without az | 17 |
cell death | 17 |
reported using | 17 |
common coronavirus | 17 |
infective agents | 17 |
dosage regimens | 17 |
vivo studies | 17 |
una estrategia | 17 |
clinically significant | 17 |
control study | 17 |
ecg monitoring | 17 |
hcq administration | 17 |
whether hcq | 17 |
two studies | 17 |
hcq concentrations | 17 |
dependent manner | 17 |
two patients | 17 |
relative risk | 17 |
supportive care | 17 |
rheumatic disease | 17 |
organ failure | 17 |
times daily | 17 |
sialic acid | 17 |
active site | 17 |
vitro data | 17 |
lo cual | 17 |
contar con | 17 |
ill covid | 17 |
clinical study | 17 |
hydroxychloroquine inhibits | 17 |
clinical symptoms | 17 |
nervous system | 17 |
vitro study | 17 |
antiviral drug | 17 |
membrane oxygenation | 17 |
el estudio | 17 |
nasopharyngeal swabs | 17 |
extracorporeal membrane | 17 |
induced qt | 17 |
cumulative dose | 17 |
effective treatment | 17 |
primary care | 17 |
complications attributed | 17 |
side chain | 17 |
class ii | 17 |
urgent need | 17 |
analysis revealed | 17 |
accepted article | 17 |
viral genome | 16 |
available evidence | 16 |
long half | 16 |
cols en | 16 |
pacientes hospitalizados | 16 |
las condiciones | 16 |
five days | 16 |
protein binding | 16 |
comparado con | 16 |
antiviral therapy | 16 |
inhibit viral | 16 |
del tratamiento | 16 |
gene expression | 16 |
virological cure | 16 |
pharmacologic treatments | 16 |
manejo del | 16 |
hospitalised patients | 16 |
sudden death | 16 |
antiviral activities | 16 |
routine care | 16 |
infectious disease | 16 |
clinical use | 16 |
hcq blood | 16 |
hcq doses | 16 |
han sido | 16 |
effect model | 16 |
antiviral treatment | 16 |
hcq prophylaxis | 16 |
avian influenza | 16 |
drug use | 16 |
los trabajadores | 16 |
hcq cq | 16 |
low risk | 16 |
hcq might | 16 |
chronic treatment | 16 |
vs low | 16 |
hydroxychloroquine retinopathy | 16 |
time points | 16 |
ventricular fibrillation | 16 |
carga viral | 16 |
allowed without | 16 |
collected data | 16 |
without permission | 16 |
qtc intervals | 16 |
en estado | 16 |
study hydroxychloroquine | 16 |
continuous variables | 16 |
reuse allowed | 16 |
patients taking | 16 |
docking studies | 16 |
registry analysis | 16 |
insulin resistance | 16 |
without diabetes | 16 |
adverse effect | 16 |
myocardial injury | 16 |
desde el | 16 |
plasmodium falciparum | 16 |
times higher | 16 |
subgroup analysis | 16 |
least one | 16 |
day followed | 16 |
literature review | 16 |
compromiso pulmonar | 16 |
multinational registry | 16 |
broad spectrum | 16 |
una vez | 16 |
innate immune | 16 |
randomized trials | 16 |
inflammatory drugs | 15 |
i fipv | 15 |
effective concentration | 15 |
hcq combined | 15 |
target cells | 15 |
clinical experience | 15 |
septic shock | 15 |
plasmodium vivax | 15 |
ii fipv | 15 |
pbs group | 15 |
cell surface | 15 |
negative conversion | 15 |
taken together | 15 |
pueden ser | 15 |
positive patients | 15 |
national institutes | 15 |
emitir una | 15 |
mediated endocytosis | 15 |
post hoc | 15 |
peripheral blood | 15 |
cardiac arrhythmia | 15 |
para su | 15 |
iron homeostasis | 15 |
life cycle | 15 |
care alone | 15 |
longest daily | 15 |
trial clinical | 15 |
exclusion criteria | 15 |
los niveles | 15 |
pacientes covid | 15 |
significant risk | 15 |
hcq chloroquine | 15 |
like receptors | 15 |
inhibit sars | 15 |
measured qtc | 15 |
patients died | 15 |
binding energies | 15 |
dificultad respiratoria | 15 |
amp synthase | 15 |
respiratory infections | 15 |
using cq | 15 |
proteolytic processing | 15 |
randomized control | 15 |
el estado | 15 |
choudhary sharma | 15 |
single center | 15 |
macrophage activation | 15 |
si se | 15 |
renal failure | 15 |
data regarding | 15 |
recomienda realizar | 15 |
significant qtc | 15 |
hydroxychloroquine alone | 15 |
treatment groups | 15 |
controlled studies | 15 |
las cuales | 15 |
cardiovascular death | 15 |
modifying antirheumatic | 15 |
daily measured | 15 |
immunomodulatory effects | 15 |
pulmonary disease | 15 |
potential treatment | 15 |
las personas | 15 |
los servicios | 15 |
virologic cure | 15 |
scientific community | 15 |
favor fundamento | 15 |
iron metabolism | 15 |
study also | 15 |
structural proteins | 15 |
lymphocyte count | 15 |
los recursos | 15 |
monoclonal antibody | 14 |
supplementary material | 14 |
asymptomatic patients | 14 |
hazard ratio | 14 |
sensitivity analysis | 14 |
significant decrease | 14 |
dose chloroquine | 14 |
endosomal acidification | 14 |
lead ecg | 14 |
clinical status | 14 |
fight covid | 14 |
antiviral agent | 14 |
faers aers | 14 |
study period | 14 |
term treatment | 14 |
drug chloroquine | 14 |
es necesario | 14 |
assessed using | 14 |
data collection | 14 |
sustained ventricular | 14 |
beneficial effect | 14 |
del personal | 14 |
qtc prolonging | 14 |
treatment strategies | 14 |
optimal dosing | 14 |
unfavorable outcome | 14 |
ha sido | 14 |
pcr test | 14 |
categorical variables | 14 |
first case | 14 |
amino acid | 14 |
pandemia covid | 14 |
confidence interval | 14 |
viral diseases | 14 |
presenting cells | 14 |
effective treatments | 14 |
clinical recovery | 14 |
entre el | 14 |
con pacientes | 14 |
pediatric patients | 14 |
asociado con | 14 |
high levels | 14 |
pooled analysis | 14 |
ms ms | 14 |
infection control | 14 |
mg times | 14 |
safety profiles | 14 |
virus adsorption | 14 |
sample sizes | 14 |
hospitalised covid | 14 |
care data | 14 |
deben ser | 14 |
el traslado | 14 |
renal disease | 14 |
como una | 14 |
donde se | 14 |
congenital malformations | 14 |
intravenous immunoglobulin | 14 |
cardiovascular complications | 14 |
flow nasal | 14 |
para evaluar | 14 |
del uso | 14 |
medical care | 14 |
entry depends | 14 |
potential risk | 14 |
infected pneumonia | 14 |
phase iii | 14 |
coronavirus sars | 14 |
respiratory support | 14 |
invasive ventilation | 14 |
controlled study | 14 |
decreased mortality | 14 |
significantly associated | 14 |
en paciente | 14 |
nasal cannula | 14 |
electronic medical | 14 |
el sars | 14 |
data extraction | 14 |
previous studies | 14 |
patient population | 14 |
ra patients | 14 |
binding affinity | 14 |
hcq dose | 14 |
un mayor | 13 |
negative effect | 13 |
el consentimiento | 13 |
estancia en | 13 |
para sars | 13 |
cq may | 13 |
nadph oxidase | 13 |
placebo group | 13 |
patients showed | 13 |
human monocytes | 13 |
serine protease | 13 |
respiratory disease | 13 |
confidence intervals | 13 |
cellular iron | 13 |
hcq treated | 13 |
using routine | 13 |
patients given | 13 |
sars patients | 13 |
low ph | 13 |
care units | 13 |
term use | 13 |
viral decline | 13 |
viral activity | 13 |
tested positive | 13 |
genetic polymorphisms | 13 |
los criterios | 13 |
therapeutic effects | 13 |
approved drug | 13 |
cause mortality | 13 |
fatality rate | 13 |
el objetivo | 13 |
among covid | 13 |
secondary outcomes | 13 |
noninvasive ventilation | 13 |
lysosomotropic agents | 13 |
chronic obstructive | 13 |
medical records | 13 |
dependent rna | 13 |
ivermectin prophylaxis | 13 |
approved drugs | 13 |
disminuir el | 13 |
nan doi | 13 |
con hipoxemia | 13 |
inhibitory effect | 13 |
drug treatment | 13 |
falla renal | 13 |
inflammatory effects | 13 |
observational comparative | 13 |
first trimester | 13 |
load reduction | 13 |
ocular toxicity | 13 |
coxiella burnetii | 13 |
en cuanto | 13 |
rpe cells | 13 |
clinically proven | 13 |
based pharmacokinetic | 13 |
endothelial cells | 13 |
receive hcq | 13 |
long term | 13 |
systemic inflammation | 13 |
del sistema | 13 |
con respecto | 13 |
require oxygen | 13 |
pk model | 13 |
higher rate | 13 |
basado en | 13 |
nitric oxide | 13 |
vero cells | 13 |
autoimmune rheumatic | 13 |
american college | 13 |
lysosomal activity | 13 |
alto riesgo | 13 |
health emergency | 13 |
reduced mortality | 13 |
endothelial dysfunction | 13 |
plasma therapy | 13 |
cancer cells | 13 |
con las | 13 |
dendritic cell | 13 |
small number | 13 |
kidney disease | 13 |
strong evidence | 13 |
severe patients | 13 |
therapeutic agents | 13 |
veroe cells | 13 |
mg dl | 13 |
un protocolo | 13 |
hospitalizados con | 13 |
missing data | 13 |
like protease | 13 |
data suggest | 13 |
clinical outcome | 13 |
viral proteins | 12 |
fold increase | 12 |
erythematosus patients | 12 |
psoriatic arthritis | 12 |
trial conducted | 12 |
random effects | 12 |
standard deviation | 12 |
cohort studies | 12 |
commons licence | 12 |
studies hydroxychloroquine | 12 |
several limitations | 12 |
clinical implications | 12 |
adaptive immune | 12 |
treatment effects | 12 |
either alone | 12 |
los primeros | 12 |
significantly reduced | 12 |
early phase | 12 |
google scholar | 12 |
ethics committee | 12 |
current knowledge | 12 |
given hcq | 12 |
frecuencia respiratoria | 12 |
significant increase | 12 |
therapeutic use | 12 |
care medicine | 12 |
hcq groups | 12 |
use hcq | 12 |
concomitant use | 12 |
left ventricular | 12 |
hcq based | 12 |
intervention arm | 12 |
en salud | 12 |
three patients | 12 |
oral administration | 12 |
health commission | 12 |
mental health | 12 |
tener en | 12 |
rheumatic drugs | 12 |
mild cases | 12 |
las muestras | 12 |
primary endpoint | 12 |
cleavage site | 12 |
available weapons | 12 |
one day | 12 |
central nervous | 12 |
los resultados | 12 |
grupo control | 12 |
promising results | 12 |
coronavirus replication | 12 |
general population | 12 |
patients may | 12 |
potential role | 12 |
cuenta con | 12 |
pacientes recibieron | 12 |
patient outcomes | 12 |
receptor ace | 12 |
dengue virus | 12 |
widespread use | 12 |
observational cohort | 12 |
findings suggest | 12 |
randomized study | 12 |
iron deficiency | 12 |
routinely collected | 12 |
antiviral efficacy | 12 |
plasma levels | 12 |
well tolerated | 12 |
el rendimiento | 12 |
retinal pigment | 12 |
arthritis patients | 12 |
las medidas | 12 |
patient characteristics | 12 |
proven protease | 12 |
renal aguda | 12 |
may increase | 12 |
early stage | 12 |
uso del | 12 |
el contexto | 12 |
cardiac disease | 12 |
rna synthesis | 12 |
treatment option | 12 |
quality evidence | 12 |
obstructive pulmonary | 12 |
multivariate analysis | 12 |
drug effect | 12 |
original data | 12 |
may lead | 12 |
vivax malaria | 12 |
label nonrandomized | 12 |
las primeras | 12 |
methodological quality | 12 |
puede emitir | 12 |
physical activity | 12 |
mayor riesgo | 12 |
studies reported | 12 |
hydroxychloroquine dosing | 12 |
way anova | 12 |
including patients | 12 |
south korea | 12 |
effective drug | 12 |
innate immunity | 12 |
mhc class | 12 |
metabolic syndrome | 12 |
antiviral properties | 11 |
randomized studies | 11 |
oral hcq | 11 |
efectos adversos | 11 |
guangdong province | 11 |
recomienda el | 11 |
related coronavirus | 11 |
french study | 11 |
sepsis campaign | 11 |
este estudio | 11 |
el nivel | 11 |
urgently needed | 11 |
positive pcr | 11 |
baseline ecg | 11 |
current pandemic | 11 |
maintenance dose | 11 |
determine whether | 11 |
four days | 11 |
ha demostrado | 11 |
taking cq | 11 |
cells infected | 11 |
treating sars | 11 |
induced myopathy | 11 |
pacientes tratados | 11 |
treatment guidelines | 11 |
mild moderate | 11 |
two different | 11 |
statistical evidence | 11 |
immune activation | 11 |
also suggested | 11 |
viral pneumonia | 11 |
inflammatory arthritis | 11 |
staphylococcus aureus | 11 |
el fin | 11 |
existe una | 11 |
stable binding | 11 |
using routinely | 11 |
aumento en | 11 |
forest plots | 11 |
como los | 11 |
malaria treatment | 11 |
respiratorio agudo | 11 |
prolonged viral | 11 |
modifying anti | 11 |
higher proportion | 11 |
composite endpoint | 11 |
protective equipment | 11 |
inflammatory responses | 11 |
deteriorated patients | 11 |
enfermedad severa | 11 |
plus az | 11 |
action potential | 11 |
signalling pathways | 11 |
clinical research | 11 |
antigen processing | 11 |
chronic kidney | 11 |
drug concentrations | 11 |
chronic hydroxychloroquine | 11 |
un paciente | 11 |
untreated cells | 11 |
mortality associated | 11 |
competing risks | 11 |
also used | 11 |
adult inpatients | 11 |
surviving sepsis | 11 |
viral particle | 11 |
placebo controlled | 11 |
cuidados paliativos | 11 |
arrhythmic manifestations | 11 |
mononuclear cells | 11 |
might also | 11 |
drug discontinuation | 11 |
ct findings | 11 |
viral envelope | 11 |
endosomal tlr | 11 |
significantly longer | 11 |
induced cardiomyopathy | 11 |
cardiovascular mortality | 11 |
saudi arabia | 11 |
animal toxicity | 11 |
covid infection | 11 |
estudio retrospectivo | 11 |
higher rates | 11 |
matched cohort | 11 |
inflammatory cytokine | 11 |
day course | 11 |
publication bias | 11 |
organic anion | 11 |
prospective cohort | 11 |
data sets | 11 |
ml min | 11 |
los siguientes | 11 |
icu patients | 11 |
without hcq | 11 |
severe side | 11 |
inhibitory effects | 11 |
por un | 11 |
alveolar macrophages | 11 |
care workers | 11 |
risk covid | 11 |
liver injury | 11 |
angiotensin converting | 11 |
oxygen saturation | 11 |
conformational changes | 11 |
although hcq | 11 |
vitro hydroxychloroquine | 11 |
commons attribution | 11 |
patient treated | 11 |
vitro efficacy | 11 |
prolonging agents | 11 |
three studies | 11 |
del equipo | 11 |
con tcz | 11 |
trial efficacy | 11 |
search terms | 11 |
sialic acids | 11 |
possible role | 11 |
including sars | 11 |
national health | 11 |
los medicamentos | 11 |
prospective study | 11 |
con mayor | 11 |
hcq compared | 11 |
respiratory infection | 11 |
antimalarial agents | 11 |
concerns regarding | 11 |
either hcq | 11 |
hospital discharge | 11 |
herpes simplex | 11 |
disease exacerbation | 11 |
mechanically ventilated | 11 |
also shown | 11 |
por coronavirus | 11 |
inflammatory diseases | 10 |
psychiatric disorders | 10 |
una mayor | 10 |
potential drug | 10 |
medical conditions | 10 |
raw data | 10 |
higher incidence | 10 |
infection chloroquine | 10 |
effects model | 10 |
el primer | 10 |
less likely | 10 |
low cost | 10 |
hcq pk | 10 |
therapeutic option | 10 |
first study | 10 |
diseases hydroxychloroquine | 10 |
patients suspected | 10 |
realizar el | 10 |
laboratory tests | 10 |
clinical setting | 10 |
cell fusion | 10 |
tomar decisiones | 10 |
fever endocarditis | 10 |
cardiac adverse | 10 |
functional receptor | 10 |
target trial | 10 |
hydroxychloroquine therapy | 10 |
disease activity | 10 |
search strategy | 10 |
renal clearance | 10 |
regression analyses | 10 |
en tiempos | 10 |
viral spike | 10 |
global health | 10 |
social media | 10 |
los respiradores | 10 |
data analysis | 10 |
anecdotal evidence | 10 |
negative pcr | 10 |
heart block | 10 |
statistical analyses | 10 |
mg three | 10 |
posted april | 10 |
oral dose | 10 |
currently used | 10 |
expression levels | 10 |
recomienda utilizar | 10 |
based treatment | 10 |
hydroxychloroquine reduces | 10 |
virus cell | 10 |
ser una | 10 |
mg hcq | 10 |
oxygen requirement | 10 |
se pueden | 10 |
higher dose | 10 |
systemic sclerosis | 10 |
early endosomes | 10 |
induced lqt | 10 |
feline coronavirus | 10 |
rhythm society | 10 |
also observed | 10 |
emerging evidence | 10 |
salud mental | 10 |
eventos adversos | 10 |
nonrandomized clinical | 10 |
limited data | 10 |
reference group | 10 |
published data | 10 |
treatment initiation | 10 |
chloroquine hcq | 10 |
como un | 10 |
chloroquine treatment | 10 |
mild symptoms | 10 |
proportional hazards | 10 |
patients affected | 10 |
significantly decreased | 10 |
recomienda considerar | 10 |
virological clearance | 10 |
major congenital | 10 |
puede considerar | 10 |
known risk | 10 |
las horas | 10 |
plasmacytoid dendritic | 10 |
confirmed sars | 10 |
infect dis | 10 |
experimental group | 10 |
usual care | 10 |
well known | 10 |
cardiac risk | 10 |
mortality among | 10 |
discharge home | 10 |
states food | 10 |
study included | 10 |
tumor growth | 10 |
systematic search | 10 |
also known | 10 |
total dose | 10 |
dis doi | 10 |
lung involvement | 10 |
use associated | 10 |
airway epithelial | 10 |
potentially lethal | 10 |
sprotein rbd | 10 |
drug development | 10 |
single dose | 10 |
hcq users | 10 |
pulmonary ct | 10 |
conduction disorders | 10 |
new drug | 10 |
simplex virus | 10 |
drug ivermectin | 10 |
compound library | 10 |
binding domain | 10 |
cardiotoxic effects | 10 |
early stages | 10 |
repurposed drugs | 10 |
hipoxemia refractaria | 10 |
hcq conjugate | 10 |
proteolytic cleavage | 10 |
tracto respiratorio | 10 |
los epp | 10 |
key role | 10 |
higher probability | 10 |
vaccine development | 10 |
ivermectin inhibits | 10 |
prone positioning | 10 |
relacionadas con | 10 |
drugs used | 10 |
el virus | 10 |
en algunos | 10 |
dose hcq | 10 |
study reported | 10 |
important role | 10 |
york city | 10 |
multicenter randomized | 10 |
healthcare settings | 10 |
study group | 10 |
concomitant qt | 10 |
lung exposure | 10 |
treatment regimen | 10 |
negative rt | 10 |
significantly different | 10 |
pcr para | 10 |
including hcq | 10 |
quality assessment | 10 |
ace expression | 10 |
nucleic acids | 10 |
en estos | 10 |
clinical decision | 10 |
drugs chloroquine | 10 |
debe considerar | 10 |
estancia hospitalaria | 10 |
molecular mechanism | 10 |
personal protective | 10 |
one month | 10 |
healthy individuals | 10 |
respiratoria aguda | 10 |
del plasma | 10 |
md simulation | 10 |
life threatening | 10 |
hydroxychloroquine tablets | 10 |
event reporting | 10 |
en esta | 10 |
medical community | 10 |
branch block | 10 |
used hcq | 10 |
inflammatory rheumatic | 10 |
elimination half | 10 |
atrioventricular block | 10 |
sensitivity analyses | 10 |
data variants | 10 |
high concentrations | 10 |
open access | 10 |
el punto | 10 |
raised concerns | 10 |
regression analysis | 10 |
clinical presentation | 10 |
lower risk | 10 |
cox proportional | 9 |
human airway | 9 |
review hydroxychloroquine | 9 |
autoimmune disease | 9 |
study performed | 9 |
like behavior | 9 |
en wuhan | 9 |
mass index | 9 |
lung model | 9 |
ill adults | 9 |
seguridad del | 9 |
medical research | 9 |
widely available | 9 |
long time | 9 |
refractory ventricular | 9 |
drug interaction | 9 |
para determinar | 9 |
early covid | 9 |
copies ml | 9 |
preventing infection | 9 |
az combination | 9 |
induced lung | 9 |
reduced risk | 9 |
greater risk | 9 |
dentro del | 9 |
therapeutic potential | 9 |
erythematosus hydroxychloroquine | 9 |
lysosome fusion | 9 |
prophylactic drug | 9 |
placebo control | 9 |
body mass | 9 |
compared hcq | 9 |
ventilated patients | 9 |
term care | 9 |
wide range | 9 |
bundle branch | 9 |
previously published | 9 |
el procedimiento | 9 |
statistical computing | 9 |
hospital death | 9 |
evitar el | 9 |
malignant ventricular | 9 |
evaluar el | 9 |
regression models | 9 |
un grupo | 9 |
national institute | 9 |
chronic hepatitis | 9 |
todas las | 9 |
dosing scheme | 9 |
green monkey | 9 |
phase i | 9 |
studies conducted | 9 |
small molecule | 9 |
el proceso | 9 |
outcome measures | 9 |
standard treatment | 9 |
mg cq | 9 |
different dosing | 9 |
corticosteroid therapy | 9 |
prolong qtc | 9 |
health systems | 9 |
pacientes sin | 9 |
electrolyte abnormalities | 9 |
acidic ph | 9 |
severe adverse | 9 |
pcr results | 9 |
iron starvation | 9 |
population pk | 9 |
clinical effects | 9 |
times day | 9 |
health crisis | 9 |
el retiro | 9 |
existe evidencia | 9 |
plasma protein | 9 |
will need | 9 |
drug safety | 9 |
envelope protein | 9 |
analyzed using | 9 |
potential inhibitors | 9 |
hcq exposed | 9 |
first days | 9 |
arm studies | 9 |
mortalidad en | 9 |
among healthcare | 9 |
transporting polypeptide | 9 |
short period | 9 |
activated protein | 9 |
possible mechanisms | 9 |
respiratory illness | 9 |
replication cycle | 9 |
protein kinase | 9 |
severe qtc | 9 |
kidney injury | 9 |
muscle cells | 9 |
en medicina | 9 |
human subject | 9 |
ic del | 9 |
limited evidence | 9 |
pregnant women | 9 |
genomic rna | 9 |
drugs strongly | 9 |
patients suffering | 9 |
antibody responses | 9 |
targeting endosomal | 9 |
developing countries | 9 |
acute kidney | 9 |
large volume | 9 |
older age | 9 |
cardiac safety | 9 |
iib clinical | 9 |
el marco | 9 |
corticosteroid treatment | 9 |
three groups | 9 |
may cause | 9 |
hcq dosing | 9 |
plasma membrane | 9 |
tlr signaling | 9 |
much higher | 9 |
transcription factor | 9 |
significantly inhibited | 9 |
active metabolite | 9 |
study protocol | 9 |
moderate grade | 9 |
animal studies | 9 |
studies show | 9 |
supplemental oxygen | 9 |
moderate cases | 9 |
kj mol | 9 |
acidic organelles | 9 |
large randomized | 9 |
lysosomal ph | 9 |
cardiac events | 9 |
por encima | 9 |
monkey kidney | 9 |
del compromiso | 9 |
contra el | 9 |
personalized medicine | 9 |
dos veces | 9 |
dependent entry | 9 |
del estudio | 9 |
radiological progression | 9 |
hydroxychloroquine chloroquine | 9 |
high mortality | 9 |
group compared | 9 |
whole blood | 9 |
also inhibit | 9 |
adverse outcomes | 9 |
entry stages | 9 |
descriptive study | 9 |
odds ratios | 9 |
lung concentrations | 9 |
binding sites | 9 |
protein complex | 9 |
risk ratio | 9 |
analysis showed | 9 |
animal model | 9 |
recently published | 9 |
immunomodulatory properties | 9 |
con sars | 9 |
study outcomes | 9 |
current study | 9 |
coronavirus spike | 9 |
el plasma | 9 |
springer nature | 9 |
cells via | 9 |
study used | 9 |
receptor signaling | 9 |
retrospective observational | 9 |
todo el | 9 |
control trials | 9 |
phase iib | 9 |
pulmonary embolism | 9 |
hoc analysis | 9 |
acute myocardial | 9 |
pharmacokinetic studies | 9 |
pk parameters | 9 |
new england | 9 |
clinical progression | 9 |
del tracto | 9 |
calculated using | 9 |
hcq exposure | 9 |
critical illness | 9 |
del inicio | 9 |
one hundred | 9 |
se considera | 9 |
pharmacological properties | 9 |
del recurso | 9 |
may help | 9 |
disease caused | 9 |
total number | 9 |
therapeutic drugs | 9 |
hydrogen bonding | 9 |
overall effect | 9 |
early outpatient | 9 |
se deben | 9 |
betulinic acid | 9 |
drug combination | 9 |
por los | 9 |
results suggest | 9 |
macrolide antibiotics | 9 |
significantly increased | 9 |
crucial role | 9 |
expert consensus | 9 |
activation syndrome | 9 |
soporte ventilatorio | 9 |
pooled risk | 9 |
pacientes adultos | 9 |
macaque model | 9 |
overall mortality | 9 |
potential anti | 9 |
reported data | 9 |
new mechanism | 9 |
icu care | 9 |
risk score | 9 |
inflammatory properties | 9 |
clinical effectiveness | 9 |
th day | 9 |
recovery time | 9 |
subject research | 9 |
sobre los | 9 |
clinical manifestations | 9 |
hcq appears | 9 |
en todos | 9 |
th cells | 9 |
dna methylation | 9 |
hcq dosage | 9 |
outcomes included | 8 |
suspected covid | 8 |
data available | 8 |
el plan | 8 |
immunomodulatory effect | 8 |
five patients | 8 |
different cell | 8 |
oral clefts | 8 |
hcq combination | 8 |
treated group | 8 |
therapeutic agent | 8 |
also associated | 8 |
subgroup analyses | 8 |
prm protein | 8 |
relatively low | 8 |
vitro experiments | 8 |
concomitant pneumonia | 8 |
published maps | 8 |
novel severe | 8 |
cuales se | 8 |
hcq efficacy | 8 |
en falla | 8 |
human ace | 8 |
standard therapy | 8 |
negative patients | 8 |
personal sanitario | 8 |
including age | 8 |
involve human | 8 |
potential antiviral | 8 |
lung disease | 8 |
computed tomography | 8 |
hcq inhibits | 8 |
invasive mechanical | 8 |
inhibiting viral | 8 |
also included | 8 |
cancer patients | 8 |
strategic national | 8 |
jurisdictional claims | 8 |
published studies | 8 |
stem cells | 8 |
blood hydroxychloroquine | 8 |
nervioso central | 8 |
coronavirus entry | 8 |
uso en | 8 |
lung cells | 8 |
urgent guidance | 8 |
severe coronavirus | 8 |
por su | 8 |
hospital setting | 8 |
aquellos pacientes | 8 |
closely related | 8 |
ongoing trials | 8 |
serum creatinine | 8 |
blood pressure | 8 |
used cq | 8 |
authors concluded | 8 |
two main | 8 |
lupus anticoagulant | 8 |
better understand | 8 |
hcq include | 8 |
los elementos | 8 |
pulmonary inflammation | 8 |
hubei province | 8 |
march th | 8 |
pneumonia outbreak | 8 |
dry cough | 8 |
post exposure | 8 |
among others | 8 |
torsadogenic potential | 8 |
global rheumatology | 8 |
trial chloroquine | 8 |
effect size | 8 |
hydroxychloroquine sulphate | 8 |
treatment effect | 8 |
los diferentes | 8 |
therapeutic drug | 8 |
human influenza | 8 |
experimental study | 8 |
may reduce | 8 |
mpro enzyme | 8 |
different countries | 8 |
ace receptors | 8 |
se le | 8 |
term hydroxychloroquine | 8 |
death rate | 8 |
pooled incidence | 8 |
un modelo | 8 |
institutional affiliations | 8 |
chloroquine chloroquine | 8 |
day post | 8 |
disease states | 8 |
cardiac ae | 8 |
pandemia por | 8 |
adjusted odds | 8 |
endoplasmic reticulum | 8 |
original author | 8 |
potential adverse | 8 |
many countries | 8 |
con falla | 8 |
specific treatment | 8 |
se presenta | 8 |
newborn mice | 8 |
enfermedad por | 8 |
vitro chloroquine | 8 |
alveolar epithelial | 8 |
endosomal nadph | 8 |
incubation period | 8 |
laboratory confirmed | 8 |
intracellular bacteria | 8 |
human organic | 8 |
reduce mortality | 8 |
discontinuation due | 8 |
complex system | 8 |
reporting system | 8 |
qtc msec | 8 |
arrhythmic safety | 8 |
qrs duration | 8 |
anion transporting | 8 |
en salas | 8 |
lung damage | 8 |
weak base | 8 |
primeras horas | 8 |
ec value | 8 |
coronavirus pandemic | 8 |
therapeutic strategies | 8 |
log copies | 8 |
med doi | 8 |
convaleciente en | 8 |
virologic efficacy | 8 |
study designs | 8 |
maximal effective | 8 |
sistema nervioso | 8 |
ordinal scale | 8 |
cell viability | 8 |
first report | 8 |
gastrointestinal symptoms | 8 |
national stockpile | 8 |
cq base | 8 |
acidic environment | 8 |
rheumatic autoimmune | 8 |
los cambios | 8 |
hiv infection | 8 |
still ongoing | 8 |
potentially fatal | 8 |
infection rate | 8 |
despite lack | 8 |
cq group | 8 |
structural basis | 8 |
antimalarial agent | 8 |
adverse drug | 8 |
scientific evidence | 8 |
skeletal muscle | 8 |
significant improvement | 8 |
immunomodulatory drugs | 8 |
el efecto | 8 |
diseases treated | 8 |
genotoxic effects | 8 |
two large | 8 |
hong kong | 8 |
short courses | 8 |
vena cava | 8 |
comorbid conditions | 8 |
disease modifying | 8 |
two major | 8 |
es posible | 8 |
rhesus macaques | 8 |
interquartile range | 8 |
total cholesterol | 8 |
trial design | 8 |
target mpro | 8 |
rheumatology alliance | 8 |
increased qtc | 8 |
novel covid | 8 |
may affect | 8 |
pacientes se | 8 |
hcq per | 8 |
hepatitis virus | 8 |
mg loading | 8 |
interaction diagrams | 8 |
authors also | 8 |
end point | 8 |
qtc monitoring | 8 |
nature remains | 8 |
insulin secretion | 8 |
crp level | 8 |
hcq studies | 8 |
moderate disease | 8 |
falsos negativos | 8 |
retrospective case | 8 |
histocompatibility complex | 8 |
en situaciones | 8 |
also indicated | 8 |
lupus patients | 8 |
hospital settings | 8 |
several countries | 8 |
tubular secretion | 8 |
different types | 8 |
lung ph | 8 |
patients also | 8 |
important lessons | 8 |
escala news | 8 |
patients requiring | 8 |
remains neutral | 8 |
entre otros | 8 |
plasma concentration | 8 |
las unidades | 8 |
significant association | 8 |
tocilizumab therapy | 8 |
molecular weight | 8 |
con base | 8 |
base en | 8 |
furosemide treatment | 8 |
monitoring protocol | 8 |
en sdra | 8 |
first time | 8 |
para establecer | 8 |
kawasaki disease | 8 |
hydroxychloroquine prophylaxis | 8 |
index date | 8 |
trials will | 8 |
vitro results | 8 |
remained significant | 8 |
hace protein | 8 |
ventricular repolarization | 8 |
soporte respiratorio | 8 |
lysosomal function | 8 |
los protocolos | 8 |
major histocompatibility | 8 |
human epithelial | 8 |
controlled case | 8 |
cq inhibits | 8 |
induced toxic | 8 |
diseases like | 8 |
con alta | 8 |
potential confounders | 8 |
many drugs | 8 |
sao fio | 8 |
malarial drugs | 8 |
potential conflicts | 8 |
ammonium chloride | 8 |
el equipo | 8 |
next days | 8 |
para lograr | 8 |
healthy subjects | 8 |
imaging findings | 8 |
fda approved | 8 |
van den | 8 |
low incidence | 8 |
se encontraban | 8 |
se realiza | 8 |
se encuentran | 8 |
todo paciente | 8 |
within hours | 8 |
may improve | 8 |
day one | 8 |
bat origin | 8 |
los participantes | 8 |
future studies | 8 |
cell receptor | 8 |
las decisiones | 8 |
least days | 8 |
autophagic flux | 8 |
symptom severity | 8 |
conduction abnormalities | 8 |
dosage regimen | 8 |
vesicular stomatitis | 8 |
chest pain | 8 |
positive sars | 8 |
china clinical | 8 |
death due | 8 |
del procedimiento | 8 |
indian council | 8 |
either drug | 8 |
associated coronavirus | 8 |
reduce viral | 8 |
nonrandomized studies | 8 |
hydroxyferroquine derivatives | 8 |
blood cells | 7 |
vina score | 7 |
hcq trials | 7 |
steady state | 7 |
analysis date | 7 |
data cleaning | 7 |
patient died | 7 |
participants took | 7 |
mediated diseases | 7 |
hydrogen bonds | 7 |
combinational therapy | 7 |
chinese clinical | 7 |
therapeutic role | 7 |
familial mediterranean | 7 |
sinha balayla | 7 |
limited sample | 7 |
consensus statement | 7 |
grade ventricular | 7 |
continuous telemetry | 7 |
treatment regimens | 7 |
treat patients | 7 |
aldosterone system | 7 |
infection hydroxychloroquine | 7 |
cutaneous lupus | 7 |
un total | 7 |
serum concentrations | 7 |
conventional treatment | 7 |
troponin i | 7 |
phase trial | 7 |
drug used | 7 |
las manifestaciones | 7 |
chinese center | 7 |
tocilizumab may | 7 |
treatment compared | 7 |
irb approval | 7 |
un hospital | 7 |
hydrogen bond | 7 |
stranded rna | 7 |
infection among | 7 |
complete heart | 7 |
nuclear factor | 7 |
para predecir | 7 |
soporte vital | 7 |
bajo flujo | 7 |
two small | 7 |
renal excretion | 7 |
excluded patients | 7 |
special reference | 7 |
pcr testing | 7 |
cell cultures | 7 |
review date | 7 |
different modes | 7 |
disease virus | 7 |
threatening covid | 7 |
hcq mox | 7 |
like disease | 7 |
used early | 7 |
discovery trial | 7 |
johns hopkins | 7 |
chloroquine analogs | 7 |
fold higher | 7 |
viral transmission | 7 |
data set | 7 |
inflammatory agent | 7 |
double blind | 7 |
los valores | 7 |
bloqueo neuromuscular | 7 |
drug concentration | 7 |
data show | 7 |
lower dose | 7 |
una herramienta | 7 |
prescribed hcq | 7 |
evidence suggests | 7 |
hydroxyl analogue | 7 |
investigators found | 7 |
assessing risk | 7 |
puede tener | 7 |
apl antibodies | 7 |
see table | 7 |
acute coronary | 7 |
ventricular hypertrophy | 7 |
i ku | 7 |
como en | 7 |
cause acute | 7 |
note springer | 7 |
approved compound | 7 |
safety results | 7 |
las metas | 7 |
proven effective | 7 |
recently reported | 7 |
trial observational | 7 |
respiratory specimens | 7 |
debe realizarse | 7 |
histoplasma capsulatum | 7 |
resource allocation | 7 |
significant change | 7 |
immunomodulatory agents | 7 |
data obtained | 7 |
oral doses | 7 |
respiratory viral | 7 |
library identifies | 7 |
en promedio | 7 |
eular recommendations | 7 |
large observational | 7 |
lung ct | 7 |
volumen corriente | 7 |
using different | 7 |
consecutive patients | 7 |
modeling approach | 7 |
tissue concentrations | 7 |
locomotor activity | 7 |
en cuidado | 7 |
african green | 7 |
common adverse | 7 |
scientific statement | 7 |
linear regression | 7 |
un procedimiento | 7 |
critical covid | 7 |
large uncertainty | 7 |
submitted work | 7 |
tract infections | 7 |
se cuenta | 7 |
concurrent use | 7 |
host defense | 7 |
previously mentioned | 7 |
old woman | 7 |
index studies | 7 |
intracellular pathogens | 7 |
pero se | 7 |
pigment epithelium | 7 |
macrolide antibiotic | 7 |
numerous studies | 7 |
cumulative doses | 7 |
american heart | 7 |
human body | 7 |
high cumulative | 7 |
old female | 7 |
hcq due | 7 |
viral life | 7 |
authors report | 7 |
related diseases | 7 |
basada en | 7 |
study results | 7 |
identificar pacientes | 7 |
del esfuerzo | 7 |
los hallazgos | 7 |
done using | 7 |
el seguimiento | 7 |
hcq levels | 7 |
block viral | 7 |
durante su | 7 |
fulminant myocarditis | 7 |
hipoxemia severa | 7 |
recurso humano | 7 |
estudio observacional | 7 |
safety data | 7 |
control studies | 7 |
may still | 7 |
phase ii | 7 |
blood samples | 7 |
hcq prep | 7 |
dose selection | 7 |
viral nucleic | 7 |
antirheumatic drug | 7 |
para identificar | 7 |
physicochemical properties | 7 |
virus clearance | 7 |
potential effect | 7 |
current status | 7 |
social distancing | 7 |
el remdesivir | 7 |
decision making | 7 |
liver enzymes | 7 |
enrolled patients | 7 |
por esto | 7 |
como las | 7 |
dose hydroxychloroquine | 7 |
para mejorar | 7 |
en mayo | 7 |
site residues | 7 |
human subjects | 7 |
hcq regimens | 7 |
peritonitis virus | 7 |
kawasaki syndrome | 7 |
safety signals | 7 |
cell transfer | 7 |
preliminary safety | 7 |
pooled prevalence | 7 |
el compromiso | 7 |
rhesus macaque | 7 |
baseline use | 7 |
identifies four | 7 |
para definir | 7 |
low molecular | 7 |
cardiovascular aes | 7 |
discharge rates | 7 |
mouse hepatitis | 7 |
relatively high | 7 |
treated cells | 7 |
las siguientes | 7 |
pandemic influenza | 7 |
significativa en | 7 |
outbreak associated | 7 |
similar findings | 7 |
hcq concentration | 7 |
relatively safe | 7 |
study date | 7 |
cq also | 7 |
endocytic pathway | 7 |
class i | 7 |
viral effects | 7 |
pregnancy outcomes | 7 |
cardiac involvement | 7 |
moderate risk | 7 |
st century | 7 |
potential conflict | 7 |
authors found | 7 |
older patients | 7 |
epigenetic mechanisms | 7 |
unchanged drug | 7 |
premature ventricular | 7 |
drugs inhibit | 7 |
medication use | 7 |
underlying cardiovascular | 7 |
golgi vesicles | 7 |
menor complejidad | 7 |
organ damage | 7 |
cardiovascular risks | 7 |
epub ahead | 7 |
robust evidence | 7 |
available clinical | 7 |
oc infection | 7 |
preclinical studies | 7 |
late endosomes | 7 |
international committee | 7 |
drug may | 7 |
disease patients | 7 |
hospitalized adults | 7 |
overall rr | 7 |
previously reported | 7 |
also increase | 7 |
severe lung | 7 |
los biomarcadores | 7 |
luego del | 7 |
thrombotic events | 7 |
see supplementary | 7 |
effect profile | 7 |
colchicine therapy | 7 |
intracellular organelles | 7 |
study showing | 7 |
neurological manifestations | 7 |
ion channel | 7 |
ataque cerebrovascular | 7 |
limited number | 7 |
low toxicity | 7 |
chronic use | 7 |
mediterranean fever | 7 |
una unidad | 7 |
series study | 7 |
troponina i | 7 |
heart association | 7 |
treat malaria | 7 |
hospital admissions | 7 |
plasma proteins | 7 |
del sars | 7 |
study cohort | 7 |
conflicting results | 7 |
realizaron un | 7 |
host immune | 7 |
asociados con | 7 |
received mg | 7 |
protein levels | 7 |
dynamics simulation | 7 |
medical record | 7 |
probable bat | 7 |
sectional study | 7 |
causal inference | 7 |
pcr positive | 7 |
el hospital | 7 |
negative results | 7 |
en dos | 7 |
gastrointestinal side | 7 |
still lacking | 7 |
inhibitor use | 7 |
qtc relationship | 7 |
line treatment | 7 |
lesser extent | 7 |
readily available | 7 |
del riesgo | 7 |
square test | 7 |
excess risk | 7 |
estudios han | 7 |
azithromycin alone | 7 |
treatment outcomes | 7 |
risk assessment | 7 |
thrombotic effects | 7 |
iron retention | 7 |
data sources | 7 |
inmunoglobulina hiperinmune | 7 |
may explain | 7 |
group showed | 7 |
cells chloroquine | 7 |
lessons learned | 7 |
first two | 7 |
million people | 7 |
outpatient setting | 7 |
renal en | 7 |
un tratamiento | 7 |
ejection fraction | 7 |
study aimed | 7 |
nucleoside analog | 7 |
drugs like | 7 |
malaria drug | 7 |
strong antiviral | 7 |
improves survival | 7 |
cancer cell | 7 |
hcq versus | 7 |
hydroxychloroquine concentration | 7 |
methodological flaws | 7 |
clinical guidelines | 7 |
una enfermedad | 7 |
un tiempo | 7 |
tropheryma whipplei | 7 |
las diferentes | 7 |
reported cases | 7 |
impaired clearance | 7 |
tissue concentration | 7 |
el soporte | 7 |
case studies | 7 |
guinea pig | 7 |
phosphate dehydrogenase | 7 |
inhibits proinflammatory | 7 |
pacientes infectados | 7 |
symptomatic disease | 7 |
ph levels | 7 |
level evidence | 7 |
corona viruses | 7 |
manuscript www | 7 |
line represents | 7 |
antiarrhythmic drugs | 7 |
cell types | 7 |
study clinical | 7 |
full text | 7 |
considerar en | 7 |
preliminary data | 7 |
showed significant | 7 |
plasma hcq | 7 |
withdrawals due | 7 |
high rate | 7 |
pcr tests | 7 |
preprint servers | 7 |
underlying diseases | 7 |
prophylactic role | 7 |
recent report | 7 |
without azn | 7 |
multicentre trial | 7 |
induced qtc | 7 |
high quality | 7 |
xanthine oxidase | 7 |
single oral | 7 |
trial data | 7 |
possible pharmacotherapies | 7 |
monoclonal antibodies | 7 |
entre otras | 7 |
riesgo para | 7 |
average treatment | 7 |
drug reactions | 7 |
las estrategias | 7 |
cellular receptor | 7 |
encouraging results | 7 |
cellular uptake | 7 |
glucose homeostasis | 7 |
potential candidates | 7 |
inflammatory markers | 7 |
therapeutic targets | 7 |
potential drugs | 7 |
platelet aggregation | 7 |
reduces fatality | 7 |
el ingreso | 7 |
tissue damage | 7 |
ill patient | 7 |
among hcws | 7 |
sinus bradycardia | 7 |
lys hotspot | 7 |
vacuolar myopathy | 7 |
body temperature | 7 |
drugs may | 7 |
generally considered | 7 |
recommended doses | 7 |
viral fusion | 7 |
studies found | 7 |
dose mg | 7 |
mg orally | 7 |
hcq seems | 7 |
un nivel | 7 |
inhibits viral | 7 |
emergency approval | 7 |
reduced lung | 7 |
growth factor | 6 |
igiv en | 6 |
nucleotide analogs | 6 |
congenital heart | 6 |
healthcare personnel | 6 |
realizado por | 6 |
respiratory rate | 6 |
therapeutic regimen | 6 |
otros pacientes | 6 |
para las | 6 |
worse outcomes | 6 |
dimer levels | 6 |
population pharmacokinetics | 6 |
tratamiento del | 6 |
like sars | 6 |
multiple organ | 6 |
effective vaccine | 6 |
influenza prevention | 6 |
los riesgos | 6 |
rna replication | 6 |
loop diuretics | 6 |
los procedimientos | 6 |
several inflammatory | 6 |
diferencias en | 6 |
hydroxychloroquine despite | 6 |
talento humano | 6 |
treatment efficacy | 6 |
potential risks | 6 |
clinical findings | 6 |
las pruebas | 6 |
healthcare system | 6 |
erythematosus due | 6 |
travel medicine | 6 |
retraso en | 6 |
label design | 6 |
orally administered | 6 |
showed good | 6 |
endothelial cell | 6 |
como se | 6 |
respondents reported | 6 |
cursan con | 6 |
evidencia directa | 6 |
hace complex | 6 |
docking analysis | 6 |
wide spectrum | 6 |
life support | 6 |
april th | 6 |
treatment assignment | 6 |
much less | 6 |
relacionados con | 6 |
el coronavirus | 6 |
good results | 6 |
en lo | 6 |
interindividual variability | 6 |
studies using | 6 |
based assays | 6 |
surface area | 6 |
del consentimiento | 6 |
three cohorts | 6 |
peer reviewed | 6 |
del respirador | 6 |
commonly reported | 6 |
donde el | 6 |
versus hcq | 6 |
endosome fusion | 6 |
gives emergency | 6 |
potential mechanisms | 6 |
reducing mortality | 6 |
en donde | 6 |
multifaceted effects | 6 |
mechanisms underlying | 6 |
en estudios | 6 |
several drugs | 6 |
data included | 6 |
detectable viral | 6 |
lung cancer | 6 |
como lo | 6 |
english language | 6 |
los factores | 6 |
patient care | 6 |
permits use | 6 |
proinflammatory signalling | 6 |
four patients | 6 |
early pregnancy | 6 |
drug response | 6 |
cell therapy | 6 |
prospective observational | 6 |
ltec values | 6 |
possible treatment | 6 |
situation report | 6 |
potent inhibitors | 6 |
falla cardiaca | 6 |
towards optimization | 6 |
immunomodulatory activity | 6 |
close monitoring | 6 |
data acquisition | 6 |
fatal outcomes | 6 |
un efecto | 6 |
ifn response | 6 |
respuesta inflamatoria | 6 |
first week | 6 |
especialmente en | 6 |
paro cardiaco | 6 |
cardiovascular adverse | 6 |
cutting edge | 6 |
many years | 6 |
patients years | 6 |
study demonstrated | 6 |
extracellular traps | 6 |
malformations associated | 6 |
renal injury | 6 |
analysis using | 6 |
similar effect | 6 |
son el | 6 |
pulmonar en | 6 |
en general | 6 |
intracellular iron | 6 |
score matching | 6 |
literature search | 6 |
recibieron tcz | 6 |
esta estrategia | 6 |
pulseless electrical | 6 |
research project | 6 |
como tratamiento | 6 |
mg dose | 6 |
day hcq | 6 |
outpatient treatment | 6 |
espacio muerto | 6 |
neither hcq | 6 |
plaquenil smpc | 6 |
biological parameters | 6 |
embo molecular | 6 |
alanine metabolite | 6 |
financial support | 6 |
safe dose | 6 |
prolongation ms | 6 |
severidad del | 6 |
potential benefits | 6 |
possible mechanism | 6 |
interim analysis | 6 |
showed clinical | 6 |
king county | 6 |
evidence regarding | 6 |
potential duration | 6 |
antiretroviral therapy | 6 |
nlrp inflammasome | 6 |
hcq sulfate | 6 |
plasma ratio | 6 |
prolongation among | 6 |
el volumen | 6 |
institutional policy | 6 |
con aumento | 6 |
contra para | 6 |
received remdesivir | 6 |
care group | 6 |
drug candidates | 6 |
likely due | 6 |
high prevalence | 6 |
small studies | 6 |
higher hcq | 6 |
requiring oxygen | 6 |
hiv aids | 6 |
forest plot | 6 |
signaling pathways | 6 |
lower bound | 6 |
potential therapies | 6 |
con menor | 6 |
interval monitoring | 6 |
systematically searched | 6 |
develop severe | 6 |
evaluated using | 6 |
upper bound | 6 |
one week | 6 |
asociada con | 6 |
terapia en | 6 |
findings may | 6 |
el covid | 6 |
renal elimination | 6 |
electrical activity | 6 |
fipv replication | 6 |
molecular descriptors | 6 |
analysis hydroxychloroquine | 6 |
reportaron una | 6 |
laboratory data | 6 |
medications used | 6 |
clinical factors | 6 |
chronic diseases | 6 |
con resultados | 6 |
elevated troponin | 6 |
hydroxychloroquine levels | 6 |
six studies | 6 |
esto se | 6 |
acute phase | 6 |
pp ab | 6 |
docking results | 6 |
series analysis | 6 |
interferon genes | 6 |
novel sars | 6 |
gov identifier | 6 |
safety surveillance | 6 |